Acute Myelogenous Leukemia (AML) Clinical Trials: Enrolling

AAML1331: A Phase 3 Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All Trans-Retinoic Acid

AAML1421: A Phase 1/2 Study of CPX-351 Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML); A Study of CPX-351 Alone Followed by Fludarabine, Cytarabine and G-CSF for Children with Acute Myeloid Leukemia (AML) That Has Come Back

AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Acute Myelogenous Leukemia (AML) Clinical Trials: No Longer Enrolling

AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for Patients with High Allelic Ratio Ratio FLT3/ITD

Trial Updates

Please check back soon for the latest information.